يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
B of A Securities Downgrades Fulcrum Therapeutics to Underperform, Lowers Price Target to $2
Fulcrum Therapeutics +1.56%
Fulcrum Therapeutics FULC | 13.00 | +1.56% |
B of A Securities analyst Tazeen Ahmad downgrades Fulcrum Therapeutics (NASDAQ:
FULC) from Neutral to Underperform and lowers the price target from $10 to $2.
